Secondary endpoints include health-related quality of life (HRQoL), MPR in patients with or without detectable EGFRm at screening in ctDNA, and the concordance of EGFR mutation status between baseline tumor DNA and ctDNA samples, as well as between local and central tumor test results. Here, EGFR is linked to neoplasm.